OTCMBNXTF
Market cap29mUSD
Jan 10, Last price
0.28USD
1D
7.93%
1Q
64.89%
IPO
-15.42%
Name
BioNxt Solutions Inc
Chart & Performance
P/E
—
P/S
106.29
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
15.34%
Rev. gr., 5y
%
Revenues
372k
+25.15%
Net income
-8m
L-37.60%
CFO
-5m
L-17.05%
Profile
BioNxt Solutions Inc. operates as a bioscience company in Germany, Switzerland, Austria, Israel, and Canada. It develops drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications; and psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. The company also develops point-of-care diagnostics comprising rapid diagnostics and biosensor screening tests for early detection and the potential for better treatment outcomes, and improved disease management; and COVID-19 PCR diagnostic kit, peri-implantitis oral biosensor, and H1N1 (swine flu) and H5N1 (avian flu) oral biosensors. In addition, it offers analytical testing and consulting services; and engages in the pathogen and oral health diagnostic and screening test, thin film drug formulation, and psychedelic pharmaceutical production and formulation businesses. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. BioNxt Solutions Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||
Revenues | 372 25.15% | 297 3.82% | |||||
Cost of revenue | 6,071 | 6,141 | |||||
Unusual Expense (Income) | |||||||
NOPBT | (5,699) | (5,843) | |||||
NOPBT Margin | |||||||
Operating Taxes | (494) | ||||||
Tax Rate | |||||||
NOPAT | (5,699) | (5,349) | |||||
Net income | (7,723) -37.60% | (12,376) -40.03% | |||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 4,426 | 6,100 | |||||
BB yield | |||||||
| Debt | |||||||
Debt current | 4,894 | 647 | |||||
Long-term debt | 3,758 | ||||||
Deferred revenue | |||||||
Other long-term liabilities | (3,724) | ||||||
Net debt | 4,530 | 4,270 | |||||
| Cash flow | |||||||
Cash from operating activities | (5,168) | (6,230) | |||||
CAPEX | (201) | (4) | |||||
Cash from investing activities | 101 | (4) | |||||
Cash from financing activities | 5,293 | 5,023 | |||||
FCF | (5,068) | (4,463) | |||||
| Balance | |||||||
Cash | 364 | 136 | |||||
Long term investments | |||||||
Excess cash | 345 | 121 | |||||
Stockholders' equity | (5,308) | (4,744) | |||||
Invested Capital | 4,919 | 4,986 | |||||
ROIC | |||||||
ROCE | 1,466.84% | ||||||
| EV | |||||||
Common stock shares outstanding | 99,323 | 83,774 | |||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | (5,503) | (5,628) | |||||
EV/EBITDA | |||||||
Interest | 1,043 | 1,143 | |||||
Interest/NOPBT | |||||||